Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720744 · ClinicalTrials.gov registry record · Phase 3
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
A Phase 3 study, sponsored by Avadel.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
NCT02720744 is a Phase 3 study that has completed, run by Avadel. The registered enrollment target is 212 participants.
The verdict
NCT02720744, a Phase 3 study, has completed, sponsored by Avadel.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether once-nightly FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.
Interventions
- DRUG Placebo
- DRUG FT218
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2016-11-17 |
| Est. Completion | 2020-03-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720744
The ClinicalTrials.gov registry entry for NCT02720744 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avadel, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02720744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02720744 about?
NCT02720744 is a clinical study titled "Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy". The purpose of this study is to determine whether once-nightly FT218 is safe and effective for the treatment of excessive daytime sleepiness and cataplexy in subjects with narcolepsy.
What is the current status of trial NCT02720744?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 2016-11-17. Estimated completion is 2020-03-25.
What interventions are being tested in trial NCT02720744?
The interventions under investigation include: Placebo (DRUG), FT218 (DRUG).
Who is sponsoring clinical trial NCT02720744?
This trial is sponsored by Avadel, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.